Andrzej CzÅ‚onkowski

List of Publications by Year
in descending order

75 papers	3,171 citations	172386 29 h-index	155592 55 g-index
75 all docs	75 docs citations	75 times ranked	2915 citing authors

#	Article	IF	Citations
1	Mechanism of action of three newly registered drugs for multiple sclerosis treatment. Pharmacological Reports, 2017, 69, 702-708.	1.5	23
2	The influence of AAV2-mediated gene transfer of human IL-10 on neurodegeneration and immune response in a murine model of Parkinson's disease. Pharmacological Reports, 2014, 66, 660-669.	1.5	35
3	Impact ofBDNF-196 G>A andBDNF-270 C>T Polymorphisms on Stroke Rehabilitation Outcome: Sex and Age Differences. Topics in Stroke Rehabilitation, 2014, 21, S33-S41.	1.0	22
4	Influence of BDNF polymorphisms on Wilsonâ€™s disease susceptibility and clinical course. Metabolic Brain Disease, 2013, 28, 447-453.	1.4	8
5	Neurochemical and Behavioral Characteristics of Toxic Milk Mice: An Animal Model of Wilsonâ€™s Disease. Neurochemical Research, 2013, 38, 2037-2045.	1.6	34
6	New single nucleotide polymorphisms associated with differences in platelets reactivity in patients with type 2 diabetes treated with acetylsalicylic acid: genome-wide association approach and pooled DNA strategy. Journal of Thrombosis and Thrombolysis, 2013, 36, 65-73.	1.0	22
7	Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes. Advances in Medical Sciences, 2013, 58, 362-368.	0.9	9
8	Effect of human interleukin-10 on the expression of nitric oxide synthases in the MPTP-based model of Parkinson's disease. Pharmacological Reports, 2013, 65, 44-49.	1.5	28
9	Potential neuroprotective effect of ibuprofen, insights from the mice model of Parkinson's disease. Pharmacological Reports, 2013, 65, 1227-1236.	1.5	39
10	Association between BDNF-196 G>A and BDNF-270 C>T polymorphisms, BDNF concentration, and rTMS-supported long-term rehabilitation outcome after ischemic stroke. NeuroRehabilitation, 2013, 32, 573-582.	0.5	27
11	The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: a subanalysis of the AVOCADO study. Kardiologia Polska, 2013, 71, 552-557.	0.3	17
12	Lack of effect of common single nucleotide polymorphisms in leukotriene pathway genes on platelet reactivity in patients with diabetes. Molecular Medicine Reports, 2013, 8, 853-860.	1.1	4
13	Effect of common single-nucleotide polymorphisms in acetylsalicylic acid metabolic pathway genes on platelet reactivity in patients with diabetes. Medical Science Monitor, 2013, 19, 394-408.	0.5	9
14	Association of plasma concentrations of salicylic acid and high on ASA platelet reactivity in type 2 diabetes patients. Cardiology Journal, 2013, 20, 170-7.	0.5	8
15	Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2 diabetes and high platelet reactivity: The AVOCADO study. Cardiology Journal, 2013, 20, 545-551.	0.5	21
16	Association of Dopamine Receptor Gene Polymorphisms with the Clinical Course of Wilson Disease. JIMD Reports, 2012, 8, 73-80.	0.7	23
17	BDNF â^'270 C>T polymorphisms might be associated with stroke type and BDNF â^'196 G>A corresponds to early neurological deficit in hemorrhagic stroke. Journal of Neuroimmunology, 2012, 249, 71-75.	1.1	31
18	Do statins influence platelet reactivity on acetylsalicylic acid therapy in patients with type 2 diabetes?. Cardiology Journal, 2012, 19, 494-500.	0.5	5

#	Article	IF	Citations
19	Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes. Journal of Thrombosis and Haemostasis, 2011, 9, 2291-2301.	1.9	46
20	Association of IL1A, IL1B, ILRN, IL6, IL10 and TNF-Î± polymorphisms with risk and clinical course of multiple sclerosis in a Polish population. Journal of Neuroimmunology, 2011, 236, 87-92.	1.1	51
21	Care for patients after stroke. Results of a two-year prospective observational study from Mazowieckie province in Poland. Neurologia I Neurochirurgia Polska, 2010, 44, 231-237.	0.6	9
22	Long-term effect of high doses glucocorticosteroids on mRNA expression for IL-6 and IL-8 in relapsed multiple sclerosis patients. Immunopharmacology and Immunotoxicology, 2010, 32, 416-421.	1.1	5
23	Association of MMP1, MMP3, MMP9, and MMP12 polymorphisms with risk and clinical course of multiple sclerosis in a Polish population. Journal of Neuroimmunology, 2009, 214, 113-117.	1.1	26
24	Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Research, 2009, 1261, 7-19.	1.1	38
25	The impact of age and gender on the striatal astrocytes activation in murine model of Parkinsonâ€™s disease. Inflammation Research, 2009, 58, 747-753.	1.6	34
26	Poststroke Service in Poland: Results of a 2-Year Prospective, Observational Study. International Journal of Stroke, 2009, 4, 318-319.	2.9	0
27	Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease. International Immunopharmacology, 2009, 9, 781-791.	1.7	23
28	PO05-MO-01 Post-stroke service in Poland. Journal of the Neurological Sciences, 2009, 285, S175-S176.	0.3	0
29	BDNF A196G and C270T gene polymorphisms and susceptibility to multiple sclerosis in the polish population. Gender differences. Journal of Neuroimmunology, 2008, 193, 170-172.	1.1	36
30	2.452 CD4+ anti-MOG lymphocytes administration improves recovery after MPTP induced injury in mice model of Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, S141-S142.	1.1	1
31	Influence of Age and Gender on Cytokine Expression in a Murine Model of Parkinsonâ€™s Disease. NeuroImmunoModulation, 2007, 14, 255-265.	0.9	26
32	MPTP-induced central dopamine depletion exacerbates experimental autoimmune encephalomyelitis (EAE) in C57BL mice. Inflammation Research, 2007, 56, 311-317.	1.6	24
33	P6 CORRELATION BETWEEN NOS EXPRESSION AND DOPAMINE CONCENTRATION IN THE STRIATUM OF C57BL/6 MICE FOLLOWING TOXIC DEGENERATION CAUSED BY 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE.. Behavioural Pharmacology, 2006, 17, 543.	0.8	0
34	P5 ROLE OF CYTOKINES IN MURINE MODEL OF PARKINSON??S DISEASE - GENDER AND AGE-RELATED DIFFERENCES.. Behavioural Pharmacology, 2006, 17, 542-543.	0.8	0
35	High dose of intravenously given glucocorticosteroids decrease IL-8 production by monocytes in multiple sclerosis patients treated during relapse. Journal of Neuroimmunology, 2006, 176, 134-140.	1.1	17
36	Ibuprofen and the mouse model of Parkinson's disease. Annals of Neurology, 2006, 59, 988-989.	2.8	14

#	Article	IF	Citations
37	A prospective study of the financial costs of multiple sclerosis at different stages of the disease. European Journal of Neurology, 2005, 12, 31-39.	1.7	45
38	Immunization with myelin oligodendrocyte glycoprotein and complete Freund adjuvant partially protects dopaminergic neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced damage in mouse model of Parkinsonâ€™s disease. Neuroscience, 2005, 131, 247-254.	1.1	15
39	Increase of matrix metalloproteinase-9 in peripheral blood of multiple sclerosis patients treated with high doses of methylprednisolone. Journal of Neuroimmunology, 2004, 146, 171-175.	1.1	15
40	Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse. Brain Research, 2004, 1019, 144-151.	1.1	41
41	Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. International Immunopharmacology, 2004, 4, 1307-1318.	1.7	106
42	Tryptase levels in patients after acute coronary syndromes: The potential new marker of an unstable plaque?. Clinical Cardiology, 2003, 26, 366-372.	0.7	67
43	Changes of percentages in immune cells phenotypes and cytokines production during two-year IFN-?-1a treatment in multiple sclerosis patients. Journal of Neurology, 2003, 250, 1229-1236.	1.8	14
44	Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson's disease. Acta Neurobiologiae Experimentalis, 2003, 63, 117-26.	0.4	33
45	Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. International Immunopharmacology, 2002, 2, 1213-1218.	1.7	69
46	Inflammatory changes in the substantia nigra and striatum following MPTP intoxication. Annals of Neurology, 2000, 48, 127-127.	2.8	13
47	Phenotyping analysis of peripheral blood leukocytes in patients with multiple sclerosis. European Journal of Neurology, 1999, 6, 347-352.	1.7	14
48	The Inflammatory Reaction Following 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Intoxication in Mouse. Experimental Neurology, 1999, 156, 50-61.	2.0	338
49	Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology, 1998, 39, 167-180.	2.0	261
50	Microglial Reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) Induced Parkinson's Disease Mice Model. Experimental Neurology, 1996, 5, 137-143.	1.7	245
51	3H-Naloxone Binding in Brain Regions of Normotensive Wistar, Spontaneously Hypertensive and Renal Hypertensive Rats. Blood Pressure, 1994, 3, 202-205.	0.7	0
52	Peripheral mechanisms of opioid antinociception in inflammation: involvement of cytokines. European Journal of Pharmacology, 1993, 242, 229-235.	1.7	127
53	Peripheral opioid receptors mediating antinociception in inflammation. Activation by endogenous opioids and role of the pituitary-adrenal axis. Pain, 1990, 41, 81-93.	2.0	61
54	Analgesic activity of morphinceptin, Î²-casomorphin-4, and deltakephalin in normotensive Wistar-Glaxo and spontaneously hypertensive rats. Peptides, 1989, 10, 539-544.	1.2	9

#	Article	IF	Citations
55	Inflammation of the hind limb as a model of unilateral, localized pain: influence on multiple opioid systems in the spinal cord of the rat. Pain, 1988, 35, 299-312.	2.0	184
56	The selective Î¹-opioid agonist, U-50,488H, produces antinociception in the rat via a supraspinal action. European Journal of Pharmacology, 1987, 142, 183-184.	1.7	22
57	Activation of periaqueductal grey pools of Î²-endorphin by analgetic electrical stimulation in freely moving rats. Brain Research, 1987, 407, 199-203.	1.1	59
58	An analysis of the â€˜toleranceâ€™ which develops to analgetic electrical stimulation of the midbrain periaqueductal grey in freely moving rats. Brain Research, 1987, 435, 97-111.	1.1	9
59	Evidence that Î¼-opioid receptors mediate midbrain â€œstimulation-produced analgesiaâ€•in the freely moving rat. Neuroscience, 1987, 22, 885-896.	1.1	19
60	Functional Response of Multiple Opioid Systems to Chronic Arthritic Pain in the Rat. Annals of the New York Academy of Sciences, 1986, 467, 182-193.	1.8	19
61	Spinal cord dynorphin may modulate nociception via a â„µ-opioid receptor in chronic arthritic rats. Brain Research, 1985, 340, 156-159.	1.1	71
62	Reduced binding of3H-spiroperidol to lymphocyte in Wilson's disease. Acta Neurologica Scandinavica, 1984, 69, 298-301.	1.0	10
63	Vasopressin and oxytocin in the rat spinal cord: Distribution and origins in comparison to [met]enkephalin, dynorphin and related opioids and their irresponsiveness to stimuli modulating neurohypophyseal secretion. Neuroscience, 1984, 13, 179-187.	1.1	56
64	Contrasting interactions of the locus coeruleus as compared to the ventral noradrenergic bundle with CNS and pituitary pools of vasopressin, dynorphin and related opioid peptides in the rat. Brain Research, 1984, 298, 243-252.	1.1	10
65	Structure-activity studies of dermorphin. Synthesis and some pharmacological data of dermorphin and its 1-substituted analogs. Journal of Medicinal Chemistry, 1983, 26, 1445-1447.	2.9	25
66	Opiate receptor binding sites in human spinal cord. Brain Research, 1983, 267, 392-396.	1.1	99
67	Lack of Postulated Opiate-Receptor Antagonistic Properties of Compound 48/80. Pharmacology, 1981, 22, 359-363.	0.9	0
68	Effects of lesions of the locus coeruleus on aggressive behavior in rats. Physiology and Behavior, 1978, 21, 695-699.	1.0	27
69	Binding of opiates and endogenous opioid peptides to neuroleptic receptor sites in the corpus striatum. Life Sciences, 1978, 22, 953-962.	2.0	40
70	The demonstration in vivo of specific binding sites for neuroleptic drugs in mouse brain. Brain Research, 1977, 130, 176-183.	1.1	80
71	Morphine action in grouped and isolated rats and mice. Psychopharmacology, 1977, 53, 191-193.	1.5	57
72	Intraspecific Aggressiveness After Lesions of Midbrain Raphe Nuclei in Rats. Pharmacology, 1975, 13, 81-85.	0.9	18

#	Article	IF	Citations
73	Role of 5-HT in the Action of Some Drugs Affecting Extrapyramidal System. Pharmacology, 1973, 10, 363-372.	0.9	39
74	The Activity of Some Neuroleptic Drugs and Amphetamine in Normal and Isolated Rats. Pharmacology, 1973, 10, 82-87.	0.9	14
75	Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated with p-chlorophenylalanine. Brain Research, 1972, 48, 443-446.	1.1	125